Cart
sales@molnova.com
Tomaralimab
CAS No. 1449294-76-1
Tomaralimab( —— )
Catalog No. M36786 CAS No. 1449294-76-1
Tomaralimab (OPN-305) is a humanized IgG4 monoclonal antibody targeting TLR2, used to study myelodysplastic syndromes (MDS).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 337 | Get Quote |
|
| 5MG | 525 | Get Quote |
|
| 10MG | 756 | Get Quote |
|
| 25MG | 1122 | Get Quote |
|
| 50MG | 1518 | Get Quote |
|
| 100MG | 1998 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTomaralimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionTomaralimab (OPN-305) is a humanized IgG4 monoclonal antibody targeting TLR2, used to study myelodysplastic syndromes (MDS).
-
DescriptionTomaralimab (OPN-305) is a humanised anti-TLR2 IgG4 monoclonal antibody. Tomaralimab has the potential for the research of Myelodysplastic Syndromes (MDS).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetTLR
-
RecptorTLR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1449294-76-1
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. GuillermoGarcia-ManeroMD, et al. A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy. Blood, 2018, 798.
molnova catalog
related products
-
Telratolimod
Telratolimod is a toll-like receptors 7/8 agonist. It has an antitumor activity.
-
Semapimod
Semapimod (CNI 1493;AXD-455) is a tetravalent guanylhydrazone that acts as a selective inhibitor of cytokine-inducible arginine transport and NO production, inhibits TLR4 signaling (IC50=0.3 uM) .
-
Enpatoran
Enpatoran is an inhibitor of TLR7(IC50 = 11.1 nM) and TLR8(IC50 = 24.1 nM). Enpatoran was found to be inactive against TLR3, TLR4, and TLR9 in vitro and in vivo.
